Our read is that taking tirzepatide is partially supported, particularly for individuals with metabolic dysfunction or obesity, but requires careful monitoring and consideration of potential side effects.
◐PARTIALLYSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
Consensus
68%
leaning supportive
Evidence quality
45/100
limited
Risk
High
specialist only
Cost / month
$$
estimated
Effort
Low
time & habit
Abstract
Tirzepatide, a dual GIP and GLP-1 receptor agonist, is supported for its dramatic effects on weight loss and improvement in metabolic markers, even at low doses. Experts like Peter Attia and Andrew Huberman highlight its efficacy in improving glucose tolerance, reducing A1C, and inducing satiety.
However, for metabolically optimized individuals, the longevity benefits are less clear and may be outweighed by harms such as reduced sleep quality due to increased heart rate, as noted by Bryan Johnson. Side effects like nausea and gastrointestinal issues are also reported, and a genetic variant can increase the risk of vomiting.
Method
Peter Attia suggests incorporating a lean mass indicator before titrating the dose of a GLP-1 agonist to monitor the body's response and guide dose adjustments. Bryan Johnson's protocol includes weekly blood tests for IGF-1, GH, GHRH, fasting glucose, insulin, HOMA-IR, ApoA1, ApoB, prolactin, and cortisol, along with continuous CGM, core body temperature, sleep, HR, and HRV monitoring to measure the success of interventions like tirzepatide microdosing after 12 weeks by retesting metabolic health markers, inflammatory markers, biological age, and body composition.
Evidence detail
01Peter Attia stated that tirzepatide at a dose of 2.5 milligrams can significantly improve glucose tolerance test results within approximately 3 to 6 months, even in individuals with severe metabolic dysfunction and without causing weight loss.
02Peter Attia's personal experiment with tirzepatide resulted in a decrease in his insulin levels to 5.0, an A1C reduction from 5.4-5.5 to 5.0, a slight weight loss of 6-7 pounds, and no loss of muscle mass due to concurrent exercise.
03Andrew Huberman noted that pharmacological interventions like GLP-1 agonists and lifestyle factors such as exercise, caloric restriction, and non-processed foods play a role in health and weight management.
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
04Andrew Huberman stated that achieving initial weight loss through medications like tirzepatide or semaglutide can lead to significant positive life changes.
05Peter Attia stated that the majority of therapeutic benefit from tirzepatide is achieved at doses of 5 to 7.5 milligrams.
06Bryan Johnson stated that success of the Tirzepatide microdosing intervention will be measured after 12 weeks by retesting metabolic health markers, inflammatory markers, biological age, and body composition.
07Peter Attia, Andrew Huberman, and Bryan Johnson collectively stated that tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown dramatic weight loss in trials for weight management and is approved for type 2 diabetes.
08Andrew Huberman considers tirzepatide and semaglutide safe and effective options for discussion, especially when they are effective.
09Peter Attia stated that tirzepatide has been remarkable in inducing a feeling of satiety.
10Peter Attia noted that long-term management of type 2 diabetes and obesity with drugs like Mounjaro in young patients depends on affordability, patient adherence, and physician expertise.
11Peter Attia stated that for a 16-year-old with an A1C of 9%, lifelong treatment with drugs like Mounjaro is necessary.
12Bryan Johnson reported that his microdose of tirzepatide (0.5 mg/week) resulted in a 1-4 bpm increase in heart rate.
Caveats
Bryan Johnson stated that for individuals already metabolically optimized, the longevity benefits of Tirzepatide are less applicable and potentially outweighed by harms like reduced sleep quality. Bryan Johnson also noted that microdosing Tirzepatide (Mounjaro) was stopped due to a 2-3 bpm increase in resting heart rate, which reduced sleep quality. Paul Saladino reported that side effects, including nausea and gastrointestinal issues, were more frequent with the highest dose (12mg) of retatrutide compared to tirzepatide, leading to an 11.3% dropout rate. Bryan Johnson further suggested that the potential longevity benefits of Tirzepatide, such as reduced dementia risk, are likely outweighed by the damage from long-term reduction in sleep quality. Rhonda Patrick highlighted that a variant in the GIPR gene is linked to an 83% higher risk of vomiting when taking tirzepatide.
What would change this verdict
Peter Attia noted that tirzepatide's effect on weight loss in people of normal body weight is not yet known, but anecdotal evidence suggests it is dose-dependent. Further research on its long-term effects on metabolically optimized individuals and its impact on sleep quality and heart rate would change the verdict.